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Abstract
Introduction The membrane cytoskeletal crosslinker ezrin
participates in several functions including cell adhesion, motility
and cell survival, and there is increasing evidence that it
regulates tumour progression. However, the role played by ezrin
in breast cancer metastasis has not been clearly delineated.
Methods We examined the role of ezrin in metastasis using a
highly metastatic murine mammary carcinoma cell line, namely
AC2M2. Stable cell clones that overexpress wild-type ezrin or a
dominant-negative amino-terminal domain of ezrin were
selected. They were then tested for cell motility and invasion in
vitro, and metastasis in a mouse in vivo tumour transplantation
model.
Results Parental AC2M2 cells and cells overexpressing wild-
type ezrin were transplanted into the mammary fat pad of
syngeneic recipient mice; these animals subsequently
developed lung metastases. In contrast, expression of the
dominant-negative amino-terminal ezrin domain markedly
inhibited lung metastasis. Consistent with this effect, we
observed that the expression of amino-terminal ezrin caused
strong membrane localization of cadherin, with increased cell–
cell contact and a decrease in cell motility and invasion, whereas
cells expressing wild-type ezrin exhibited strong cytoplasmic
expression of cadherins and pseudopodia extensions. In
addition, inhibitors of phosphatidylinositol 3-kinase and c-Src
significantly blocked cell motility and invasion of AC2M2 cells
expressing wild-type ezrin. We further found that overexpression
of amino-terminal ezrin reduced levels of Akt pS473 and
cytoskeletal-associated c-Src pY418 in AC2M2 cells, which
contrasts with the high levels of phosphorylation of these
proteins in cells expressing wild-type ezrin. Phosphorylated
Erk1/2 was also reduced in amino-terminal ezrin expressing
cells, although a mitogen-activated protein kinase kinase (MEK)
inhibitor had no detectable effect on cell motility or invasion in
this system.
Conclusion Our findings indicate that ezrin is required for
breast cancer metastasis, and that c-Src and
phosphatidylinositol 3-kinase/Akt are effectors of ezrin in the cell
motility and invasion stages of the metastatic process. Together,
these results suggest that blocking ezrin function may represent
a novel and effective strategy for preventing breast cancer
metastasis.
Introduction
Deregulation of cell–cell contact, increased cell motility and
invasion of carcinoma cells are key steps in the metastatic cas-
cade [1], but the rate-limiting signalling steps that regulate this
process in early-stage breast cancer have not yet been identi-
fied. One important molecule is the membrane cytoskeletal
crosslinker protein ezrin, a member of the ezrin–radixin–
moesin family, which is well documented to regulate several
cytoskeletal-related functions, including cell adhesion, cell sur-
vival and cell motility [2-6]. There is also increasing evidence
that ezrin regulates tumour progression [3]. Comparison of
gene expression profiles in paired metastatic and nonmeta-
static tumour cell lines and tissue samples revealed a strong
increase in ezrin expression in metastases from rodent mam-
mary and human pancreatic and colorectal carcinomas [7,8].
Likewise, ezrin exhibited strong expression in a variety of inva-
sive human cancers, including osteosarcomas, melanomas,
astrocytic tumours, and pancreatic, lung and endometrialR365
HGF = hepatocyte growth factor; MAPK = mitogen-activated protein kinase; MEK = mitogen-activated protein kinase kinase; PBS = phosphate-buff-
ered saline; PI3K = phosphatidylinositol 3-kinase; SD = standard deviation; VSVG = vesicular stomatitis virus glycoprotein.
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pression of ezrin protein function abrogates pulmonary metas-
tases of murine rhabdomyosarcoma [13] and osteosarcoma
cells [14], suggesting that ezrin may be a key regulatory mole-
cule in malignant disease. However, the role played by ezrin in
breast cancer metastasis has not been delineated.
Ezrin is regulated by an intramolecular association of its amino-
terminal and carboxyl-terminal domains that masks their pro-
tein–protein binding sites [2]. Unfolding of the molecule into
an active conformation occurs following binding to phosphoi-
nositides and phosphorylation on the carboxyl-terminal threo-
nine 567 [15]. The open molecule binds various membrane-
associated adhesion molecules and ion exchangers to the
amino-terminal region [2], and polymerized F-actin via the car-
boxyl-terminal domain [16]. Ezrin is involved in signal transduc-
tion pathways that depend on tyrosine kinases. Stimulation of
cells with epidermal growth factor [17] or hepatocyte growth
factor (HGF) [6] results in phosphorylation of ezrin primarily at
two tyrosine residues (Tyr145 and Tyr353), which are impor-
tant in regulating ezrin function. Phosphorylation of ezrin at
these two tyrosine residues is required for tubulogenesis and
motility [6], and Tyr353 regulates a phosphatidylinositol 3-
kinase (PI3K)/Akt-dependent cell survival pathway through
association with the p85 subunit of PI3K [5].
Our laboratory developed a mouse mammary carcinoma cell
line, SP1, for studies of tumour progression and metastasis
[18]. The parent SP1 cells form cadherin-based cell–cell con-
tacts, exhibit oestrogen-dependent primary tumour growth fol-
lowing transplantation in vivo, and are poorly metastatic.
Recently, we showed that ezrin acts cooperatively with acti-
vated c-Src in deregulating cadherin-based cell–cell contacts
and scattering of SP1 cells [19]. We further showed that
blocking ezrin function by overexpressing a truncated domain
(amino-terminal amino acids 1–309) of ezrin, which has domi-
nant-negative function [6], abrogates cell scattering and
enhances cadherin-based cell–cell contacts in SP1 cells [19].
These findings prompted us to examine the role played by
ezrin in cell invasion and metastasis of breast carcinoma cells.
For this study, we used a highly metastatic variant cell line,
namely AC2M2, selected from rare metastatic nodules of SP1
cells in vivo [18]. AC2M2 cells exhibit strong cytoplasmic
localization of cadherins and extensive filopodia with weak
cell–cell contacts. Our findings show that overexpression of
the dominant negative amino-terminal ezrin mutant in AC2M2
cells abrogates in vivo metastasis and inhibits cell motility and
invasion in vitro. Furthermore, cells overexpressing the amino-
terminal ezrin mutant showed marked reduction in PI3K/Akt,
Erk1/2 and c-Src activities, indicating a possible role for these




Rabbit anti-sheep IgG conjugated with horseradish peroxi-
dase was from Jackson ImmunoResearch Laboratories (West
Grove, PA, USA). Mouse (monoclonal) anti-pan cadherin anti-
body was obtained from Sigma Immunochemicals (Oakville,
Ontario, Canada). Alexa-488-conjugated goat anti-mouse IgG
was obtained from ICN Biomedicals (Mississauga, Ontario,
Canada). Mouse monoclonal antibody against the vesicular
stomatitis virus glycoprotein (VSVG; clone P5D4) was
obtained from Roche Diagnostics (Mississauga, Ontario, Can-
ada). Rabbit anti-ezrin IgG (carboxyl-terminus specific) was
prepared as described previously [6]. Antibodies against the
phosphorylated forms of Akt pS473, Erk1/2 pT185/pY187
and c-Src pY418 (i.e. phospho-specific antibodies), and cor-
responding pan-Akt and pan-Erk1/2 antibodies were obtained
from Medicorp (Montreal, Quebec, Canada). Pan c-Src anti-
body (Ab-1) was obtained from Oncogene Science (Cam-
bridge, MA, USA), and Matrigel was obtained from Becton
Dickinson Co. (Mississauga, Ontario, USA). The PI3K inhibitor
LY294002, the c-Src inhibitor SU6656 and the mitogen-acti-
vated protein kinase (MAPK) kinase (MEK) inhibitor
PD098059 were obtained from Calbiochem (San Diego, CA,
USA).
Cell lines and tissue culture
The SP1 tumour cell line was derived from a spontaneous,
poorly metastatic murine mammary intraductal adenocarci-
noma, isolated from a female CBA/J retired breeder [18].
AC2M2 cells are a highly metastatic variant selected from the
SP1 cell line following three times serial passage of a lung
metastatic nodule into the mammary fat pad of syngeneic
mice, as described previously [18]. Cell lines were cultured in
Dulbecco's modified Eagle medium (Invitrogen, Burlington,
Ontario, Canada) supplemented with 7% foetal bovine serum.
Cell transfection
The pCB6 vector containing cDNA encoding VSVG-tagged
ezrin or the VSVG-tagged amino-terminal truncated domain
(amino acids 1–309) of ezrin was previously described [6]. All
transfections were carried out with Lipofectamine Plus rea-
gent (Canadian Life Technology, Burlington, Ontario, Canada)
in accordance with the manufacturer's instructions. Stable
transfectants were selected with G418 (450 µg/ml; Sigma-
Aldrich, Oakville, Ontario, Canada) and individual clones were
isolated. Exogenous protein expression in each clone was
confirmed using indirect immunofluorescence (data not
shown) and semiquantitative western blot analysis.
Indirect immunofluorescence
Indirect immunofluorescence staining was conducted as pre-
viously described [19]. Briefly, cells were plated overnight on
cover slips, fixed in 3% paraformaldehyde/phosphate-buffered
saline (PBS), permeabilized with 0.2% Triton X-100 and
blocked for 30 min with 3% bovine serum albumin. Cells were
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priate secondary antibody. Preparations were observed using
a Leica TCS SP2 confocal microscope (Leica Microsystems,
Richmond Hill, Ontario, Canada) in the Queen's Cancer
Research Institute and Protein Discovery and Function Facility.
Image acquisitions were processed using Adobe Photoshop
software.
Western blotting
Cells were grown to 60% confluence in six-well tissue culture
plates (NUNC, Mississauga, Ontario, Canada), rinsed with
ice-cold PBS with 0.1 µmol/l CaCl2 and 0.1 µmol/l MgCl2
(PBS*), and lysed in 2× Laemmli buffer. For blotting with phos-
pho-specific antibodies, cells were serum-starved overnight
and plated on fibronectin-coated (10 mg/ml) plates for the
times indicated. For analysis of c-Src, the cytoskeletal fraction
was first extracted by a 1-min incubation with 250 µl of a Triton
X-100 buffer (soluble fraction) that preserves cytosketal-asso-
ciated material (csk buffer: 50 mmol/l MES, 3 mmol/l EGTA, 5
mmol/l MgCl2, 0.5% Triton X-100; pH 6.4). The remaining cel-
lular material (insoluble fraction) was rinsed quickly with 500
µl csk buffer, and was further extracted with 250 µl 2× Lae-
mmli buffer. Protein determination of cell lysates was per-
formed using a DC protein assay kit (Biorad, Mississauga,
Ontario, Canada). All cell lysates were subjected to 10%
SDS-PAGE under reducing conditions (with 2.5% β2-mercap-
toethanol) and transferred to PVP (polyvinylpyrrolidone) mem-
branes. The membranes were blocked and probed with the
appropriate primary and secondary antibodies, followed by
chemiluminescence with the Northern Lightning™ reagent
(Perkin Elmer Life Sciences Inc., Boston, MA, USA). Semi-
quantitation of exogenous versus endogenous ezrin expres-
sion was determined by western blotting of serial dilutions of
total cell lysates (0.6–20 µg), as described previously [6,19].
The fold increase in exogenous ezrin expression was deter-
mined by comparing the titration end-point of the correspond-
ing ezrin band in each clone with that of cells transfected with
empty pCB6 vector. For amino-terminal ezrin expressing
clones, the ratio of VSVG–amino terminal ezrin to endogenous
ezrin normalized to actin was calculated using densitometric
analysis.
Tumour transplantation and metastasis
SP1 and AC2M2 cell lines were injected (7.5 × 103 cells in 10
µl/mouse) into the mammary fat pad of syngeneic mice, as
described previously [18]. Primary tumour growth was moni-
tored every 2–3 days, and metastasis in lung, viscera, liver and
draining lymph nodes was assessed 6 weeks later. Histologi-
cal analysis of tissue sections stained with haematoxylin and
eosin was performed to confirm the presence of metastases in
the various organs. Based on the gross and histological anal-
yses, animals were assessed as positive or negative with
respect to metastasis. At least eight mice were included in
each group.
Wound healing assay
Cells were plated onto 12-well tissue culture dishes (NUNC)
at near confluence in complete tissue culture medium. Conflu-
ent cells were scored using a 20 µl Eppendorf micropipette
tip. The medium was immediately replaced, and spontaneous
cell migration was monitored using a Nikon inverted micro-
scope for 18–24 hours, as indicated. For experiments compar-
ing transfected clones, analysis at 18 hours is shown because
maximal differences between groups were observed at this
time. For experiments with pharmacological inhibitors, the
assay was allowed to proceed for 24 hours to optimize the
effect of the inhibitors. Viability of cells was maintained during
this assay period. Phase contrast images were captured, and
the distance of wound closure (compared with control at t = 0
hours) was measured in three independent wound sites per
group. Relative cell motility was calculated as the wound width
at t = 0 hours minus the wound width at t = 18–24 hours, as
indicated. Values from at least three independent experiments
were pooled and expressed as mean ± standard deviation
(SD).
Invasion assay
Transfected AC2M2 cells were plated in 24-well transwell cul-
tures (NUNC). Cells (5 × 104) were overlayered in 200 µl of
0.5% foetal bovine serum/Dulbecco's modified Eagle medium
on Matrigel-coated transwell membranes (8 µm pore size), and
with 0.5 ml of complete medium in the lower chamber. After
36–48 hours (as indicated) the cells were fixed and stained
with Harris's modified haematoxylin (Fisher Scientific, Nepean,
Ontario, Canada), and noninvading cells on the top of the
membrane were removed using a Q-tip. The membranes were
then mounted on glass slides, and images corresponding to
the entire membrane surface were captured using an Olympus
inverted microscope equipped with a CCD camera (Apogee
Instruments Inc., Auburn, CA, USA). The total numbers of cells
invading through the membrane were quantitated using
ImagePro software (Symbol Technologies, Mississauga,
Ontario, Canada). Values were normalized to empty pCB6
vector group in each experiment, and the results from at least
three independent experiments were pooled and expressed as
mean relative cell invasion ± SD.
Statistical analysis
Statistical significance among metastasis groups was deter-
mined using the two-sided Fisher's exact test. The day at
which tumours reached 1 cm diameter was determined by lin-
ear regression analysis of growth curves from individual mice,
and expressed as mean ± SD. Statistical significance between
groups in the motility and invasion assays was assessed using
a Fisher's two-tailed t-test with Microsoft Excel software.
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Overexpression of amino-terminal ezrin inhibits 
metastasis of AC2M2 breast carcinoma cells
We previously showed that overexpression of a truncated
amino-terminal domain of ezrin blocks HGF-induced migration
and morphogenesis of epithelial cells [6], and reduces cell
scattering in SP1 carcinoma cells expressing activated c-Src
[19]. We therefore examined the effect of amino-terminal ezrin
on invasion and dissemination of a highly metastatic mammary
carcinoma variant cell line, namely AC2M2, which is derived
from SP1 cells. We generated stable transfectants of AC2M2
cells expressing VSVG-tagged wild-type and amino-terminal
ezrin in a pCB6 eukaryotic expression vector, as described
previously [6]. Ezrin protein levels in clones transfected with
pCB6 vector containing wild-type ezrin were found to be
increased approximately 4-fold and 8-fold, respectively, in
WTC4 and WTC6 cells compared with cells transfected with
empty vector, as determined by semiquantitative western blot-
ting (Fig. 1a). Expression of amino-terminal ezrin was
increased 1.6-fold and 4.5 fold, respectively, in NTC6 and
NTC7 cells compared with endogenous ezrin and normalized
to actin, as determined by densitometric analysis (Fig. 1b).
AC2M2 cells transfected with empty pCB6 vector, or overex-
pressing wild-type ezrin exhibited strong cytoplasmic expres-
sion of cadherins and filopodia extensions (Fig. 1c–e). In
contrast, overexpression of amino-terminal ezrin expression
caused strong membrane localization of cadherins with
increased cell–cell contacts (Fig. 1f,g).
To assess the role of ezrin function in metastasis, clones of
AC2M2 cells overexpressing wild-type ezrin or amino-terminal
ezrin were injected into the mammary fat pad of syngeneic
female mice, and metastases were assessed 6 weeks after
injection (Table 1). No change in primary tumour growth rate
was observed, as assessed by percentage primary tumour
take and day of 1 cm tumour diameter, except for one amino-
terminal expressing clone (NTC6), which showed reduced
tumour growth rate. To compensate, mice in this group were
killed approximately 1 week later to allow all tumours to grow
to an equivalent size. Untransfected AC2M2 cells exhibited
extensive pulmonary metastases (10/11), as compared with
the poorly metastatic parent SP1 cells (3/13; P = 0.003).
Pooled AC2M2 cells transfected with empty pCB6 vector (7/
8) or two clones overexpressing wild-type ezrin (13/15 and 6/
7) were also strongly metastatic. In contrast, expression of
amino-terminal ezrin caused a marked reduction in metastases
in two independent clones (0/8 and 3/8; P < 0.0001 and P =
0.002, respectively). Similar results were obtained with an
additional amino-terminal ezrin overexpressing clone (NTB8)
from an independent transfection (0/5; P = 0.002). Analysis of
pooled results showed that metastases in the three amino-ter-
minal ezrin groups (3/21) were strongly reduced compared
with the two wild-type ezrin groups (19/22; P < 0.0001).
Histological analysis of various organ sites in animals with
tumours transfected with empty pCB6 vector or wild-type
ezrin (WTC4, WTC6) revealed massive tumour nodules in the
lung (Fig. 2a,b), as well as occasional metastases in the small
intestine (data not shown). In contrast, the majority of mice
injected with tumour cells overexpressing amino-terminal ezrin
(NTC6, NTC7, NTB8) showed no metastatic lesions; the few
metastases that did form (in the NTC7 group) were generally
smaller and primarily localized to vascular channels (Fig. 2c,d).
These findings suggest that ezrin function is necessary for
metastasis in this breast cancer model.
Figure 1
Localization of cadherins in metastatic mammary carcinoma cells over-expressing wild-type a d amino-terminal ezrin
expressing wild-type and amino-terminal ezrin. Metastatic AC2M2 cells 
were transfected with empty pCB6 vector, or a vector encoding wild-
type or amino-terminal ezrin, as described in the text. (a) Serial dilutions 
of the total cell extracts (0.6–20 µg) were subjected to reduced 10% 
SDS-PAGE and transferred to PVP membranes. The membranes were 
probed with anti-ezrin and anti-actin antibodies, followed by the appro-
priate peroxidase-conjugated secondary antibodies, and developed 
with chemiluminescence. Lanes from left to right contained 10 µg of 
the following cell extracts: pooled AC2M2 cells transfected with empty 
pCB6 vector, and two clones transfected with wild-type (WT) ezrin. 
WTC4 and WTC6 exhibited 4-fold and 8-fold overexpression, respec-
tively, of ezrin compared with vector control cells. (b) Membranes were 
probed with anti-vesicular stomatitis virus glycoprotein (VSVG), anti-
ezrin and anti-actin antibodies. Lanes contained 15 µg of cell extracts 
from pooled pCB6-transfected cells, and two clones transfected with 
amino-terminal ezrin. Clones NTC6 and NTC7 exhibited 1.6-fold and 
4.6-fold amino-terminal ezrin expression, respectively, compared with 
endogenous ezrin, as determined by densitometric analysis of VSVG 
and ezrin blots normalized to actin. (c-g) The above cell lines were 
immunostained with anti-pan cadherin antibody, as described the text. 
Representative confocal microscope images are shown.
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motility and invasion of AC2M2 cells
Metastasis is a multistep process involving intravasation,
transport through the vasculature or lymphatics, and extrava-
sation into target organs [20]. Previous studies indicated a
role for ezrin in HGF-induced cell scattering and migration
[6,19]. We therefore examined the role played by ezrin in cell
motility and invasion of metastatic AC2M2 cells. Wound heal-
ing assays were conducted using AC2M2 cells transfected
with empty pCB6 vector or a vector encoding wild-type ezrin
or amino-terminal ezrin. A wound was scored on a cell monol-
ayer, and the wound closure was assessed at various times up
to 24 hours. Our results show that expression of amino-termi-
nal ezrin reduced the ability of AC2M2 cells to close the
wound by approximately 2.5-fold compared with cells trans-
fected with empty pCB6 vector or with wild-type ezrin (Fig.
3a). Invasion assays were carried out using Matrigel-coated
transwell culture chambers, and invading cells were counted
after 36–48 hours using image analysis. AC2M2 cells
expressing wild-type ezrin showed increased cell invasion
compared with cells transfected with empty pCB6 vector,
whereas amino-terminal ezrin expressing clones exhibited
markedly reduced cell invasion (Fig. 3b).
PI3K and c-Src are required for ezrin-mediated cell 
motility and invasion of AC2M2 cells
PI3K, c-Src and MAPK pathways have been implicated in cell
motility and invasion in many cell types [21]. As a first step in
unravelling the signalling pathways involved in cell motility and
invasion of AC2M2 cells overexpressing wild-type ezrin, we
determined the effect of specific signal transduction inhibitors
on these functions. The results showed that the PI3K inhibitor
LY294002 markedly attenuated cell motility (3-fold) of two
clones overexpressing wild-type ezrin as well as cells trans-
fected with empty pCB6 vector (data not shown; Fig. 4a,b).
The c-Src inhibitor SU6656 had a moderate (1.5-fold) block-
ing effect on cell motility. In contrast, the MEK inhibitor
PD098059 had no detectable effect. In addition, cell invasion
was dramatically inhibited by both PI3K and c-Src inhibitors,
but not by the MEK inhibitor (Fig. 4c). All three inhibitors at the
concentrations indicated were previously shown to block
activity of the respective kinases, as determined by western
blotting with the corresponding phospho-specific antibodies
[22] (data not shown). Thus, PI3K and c-Src pathways, but not
the MAPK pathway, are required for both cell motility and inva-
sion of wild-type ezrin-expressing AC2M2 cells.
Overexpression of amino-terminal ezrin abrogates 
signalling through PI3K/Akt, c-Src, and MAPK pathways 
in AC2M2 cells
The results shown in Fig. 4a–c raise the possibility that PI3K
and c-Src are downstream of ezrin in the regulation of cell
motility and invasion in AC2M2 cells. To investigate this
notion, we examined the effect of amino-terminal ezrin on
phosphorylation of Akt S473 (a downstream effector of PI3K
[5]), c-Src Y418 (within the c-Src catalytic domain [1]) and
Erk1/2 T185/Y187 (within the activation loop of Erk1/2; Fig.
4d). Serum-starved AC2M2 cells were plated on fibronectin
Table 1
Expression of amino-terminal ezrin inhibits metastasis of breast carcinoma cells
Cell linea Transfected with Primary tumour takes (%) Day of 1 cm tumour diameterb Day of sacrifice Metastasis (%)c
SP1 None 100% (13/13) 24 ± 7 35 23% (3/13)
AC2M2 None 100% (11/11) 30 ± 5 41 90% (10/11)†
pCB6 Vector 100% (8/8) 33 ± 4 39 88% (7/8)
WTC4 WT ezrin 100% (7/7) 28 ± 4 41 88% (6/7)
WTC6 WT ezrin 100% (15/15) 26 ± 2 39 87% (13/15)
NTC6 N-term ezrin 38% (3/8) 40 ± 10* 47 0% (0/8)‡
NTC7 N-term ezrin 100% (8/8) 28 ± 1 39 38% (3/8)‡
NTB8d N-term ezrin 100% (5/5) 29 ± 3 41 0% (0/5)‡
aPoorly metastatic parental SP1 cells or highly metastatic variant AC2M2 cells alone, or transfected with empty pCB6 vector, or a vector encoding 
wild-type (WT) ezrin or amino-terminal (N-term) ezrin, were transplanted (7.5 × 103 cells) into the mammary fat pad of syngeneic mice (see text). 
bDay to 1 cm tumour diameter was calculated by linear regression analysis of data from individual mice. Values are expressed as mean ± standard 
deviation. Clone NTC6 showed a significant increase (*) in the day of 1 cm tumour diameter compared with WTC4 and WTC6 (P = 0.012). Mice 
with NTC6 tumours were therefore killed approximately 1 week later to allow tumour growth to a comparable size. cAC2M2 cells showed 
significantly more metastases than did the parental SP1 cells (†P = 0.003; Fisher's exact test). Pooled results from three N-term ezrin expressing 
clones showed a significant reduction in metastases compared with two WT ezrin expressing clones (‡P < 0.0001). Individual P values for NTC6, 
NTC7 and NTB8 are as follows (respectively): <0.0001, 0.002 and 0.002. dNTB8 is an N-term ezrin-expressing clone derived from an 
independent transfection of AC2M2 cells, and was transplanted as described above.
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ting with the appropriate phospho-specific antibodies. Inter-
estingly, expression of Akt pS473 was increased in metastatic
AC2M2 cells (empty vector) compared with the poorly meta-
static parental SP1 cells. Overexpression of amino-terminal
ezrin, compared with wild-type ezrin, markedly reduced the
level of Akt pS473 in AC2M2 cells, indicating regulation by
ezrin of the PI3K/Akt pathway in these cells. In parallel, the
level of phospho-Erk1/2 (pT185/pY187) was sustained in
AC2M2 cells transfected with empty pCB6 vector or wild-type
ezrin, and was reduced in cells expressing amino-terminal
ezrin. Because activated c-Src associates with its substrate at
the focal adhesion complex [1,23], we examined c-Src pY418
in both the Triton X-100 soluble and insoluble (cytoskeletal-
associated) fractions in AC2M2 cells (Fig. 4e). Our results
show that the levels of cytoskeletal-associated total c-Src and
c-Src pY418 were increased in cells overexpressing wild-type
ezrin, but were markedly reduced in cells expressing amino-
terminal ezrin. In contrast, the level of c-Src pY418 in the sol-
uble fraction (and in total cell lysates; data not shown)
remained unchanged in all cell groups. Thus, ezrin plays a key
role in stabilizing the activities of PI3K and c-Src, as well as
Erk1/2.
Discussion
In the present study we demonstrate for the first time that ezrin
function is required for metastasis of breast carcinoma cells.
Our results show that inactivating ezrin function by
Figure 2
Expression of amino-terminal ezrin significantly reduces lung metas-tases of carcinoma cells
tases of carcinoma cells. Metastatic AC2M2 cells transfected with 
empty pCB6 vector or a vector encoding wild-type ezrin or amino-termi-
nal ezrin were injected (7.5 × 103/mouse) into the mammary fat pad of 
syngeneic mice, and metastasis was assessed 6 weeks later, as 
described in the text. Images are shown from tissue sections from the 
lungs of mice injected with AC2M2 cells transfected with (a) empty 
pCB6 vector, (b) wild-type ezrin (WTC4), or (c,d) amino-terminal ezrin, 
stained with haematoxylin and eosin. Normal lung tissue is indicated by 
'NL'. Tumour metastases are indicated by 'T'. Arrows indicate endothe-
lial lining of vascular channels with tumour emboli. Original magnifica-
tions: panels a–c, 200×; panel d, 400×.
Figure 3
Expression of amino-terminal ezrin inhibits motility and invasion of carci-noma cells
noma cells. (a) Transfected AC2M2 clones (see Fig. 1) were grown to 
confluence in 12-well NUNC tissue culture plates with 2 ml of 10% foe-
tal bovine serum (FBS)/Dulbecco's modified Eagle medium (DMEM). 
Cultures were wounded by streaking cell monolayers with a 20 µl 
Eppendorf micropipette tip and monitored up to 24 hours, as described 
in the text. Representative fields photographed after 18 hours are 
shown. Vertical bars indicate the wound distance. Bar, 50 µm. (b) 
Transfected AC2M2 cells were subjected to an invasion assay, as 
described in the text. Cells (5 × 104) were over-layered in 200 µl of 
0.5% FBS/DMEM medium on the transwell membranes (8 µm pore 
size), with 0.5 ml of complete medium in the lower chamber. After 36–
48 hours, cells were fixed and stained with modified haematoxylin, and 
cells invading through the membrane were counted using ImagePro 
software, as described in the text. The numbers of invading cells were 
normalized to empty pCB6 vector group in each experiment. The 
results from at least three independent experiments were pooled, and 
expressed as the mean relative cell invasion ± standard deviation. 
Asterisks indicate (**) a significant increase or (*) a significant reduction 
in cell invasion compared with vector control, using a two-sided Fisher's 
t-test. P = 0.03 for WTC4**; P = 0.009 for NTC6*; and P = 0.02 for 
NTC7*.
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mutant blocks spontaneous pulmonary metastases of mam-
mary carcinoma cells transplanted into the orthotopic site. We
further show that overexpression of wild-type ezrin increases
carcinoma cell invasion, whereas amino-terminal ezrin causes
reduced cell scattering, motility and invasion, thus indicating a
possible mechanism by which ezrin regulates progression to
invasive cancer. Similar reports have shown that overexpress-
ing ezrin antisense [13] or an ezrin T567A dominant-negative
mutant [14] blocks both experimental and spontaneous
metastasis of murine rhabdomyosarcoma and osteosarcoma
cells, and in the latter report the rate-limiting effect was dem-
onstrated to be on early survival of metastastic cells. Thus,
ezrin may have multiple effects on the metastatic cascade.
Figure 4
Role of phosphatidylinositol 3-kinase (PI3K) and c-Src in ezrin-mediated cell motility and invasion. (a) In a wound healing experiment with WTC4 
cells, the PI3K inhibitor LY294002 (10 µmol/l), the c-Src inhibitor SU6656 (10 µmol/l), or the mitogen-activated protein kinase kinase (MEK) inhibi-
tor (PD098059; 30 µmol/l), or the solvent DMSO (dimethyl sulfoxide; 10 µl/culture) was added to cultures, and wound closure was monitored up to 
24 hours, as described for Fig. 3a. Representative fields photographed after 24 hours are shown. (b) The histogram shows pooled results from 
clones WTC4 and WTC6 in three independent wound healing experiments with the above inhibitors. Significant reduction in motility was observed 
in groups treated with LY294002 (P= 0.002) and SU6656 (P = 0.03). (c) WTC4 cells were set up in transwell cultures with PI3K, c-Src, or MEK 
inhibitors at the concentrations indicated above, and cell invasion was assessed after 36 hours. Results are expressed as the mean cell invasion ± 
standard deviation of at least three independent experiments. Single asterisk (*) indicates a specific reduction in invasion compared with DMSO-
treated cells (LY294002, P = 0.02; SU6656, P = 0.02). (d) For analysis of Akt and Erk1/2 activation, transfected AC2M2 cell lines (see Fig. 1a) 
were serum starved overnight and cultured on fibronectin substratum (10 µg/ml) for 45 min. Cells were then lysed, and equal protein amounts of 
each cell lysate were subjected to 10% SDS-PAGE under reduced conditions. Proteins were transferred to PVP membranes, and western blotting 
was carried out with antibodies against Akt pS473, pan-Akt, Erk1/2 pT185/pY187 and pan-Erk1/2. (e) For c-Src analysis, cells were plated for 2 
hours on fibronectin substratum and cell lysates of Triton X-100 soluble and insoluble (cytoskeletal-associated) fractions were prepared, as 
described in the text. Blots were probed with antibodies against c-Src pY418 and pan c-Src.
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does not augment metastasis of parental SP1 cells. Further-
more, no increase in expression of endogenous ezrin was
observed in the metastatic (AC2M2) compared with the par-
ent SP1 cell lines (data not shown). These findings imply that
overexpression of ezrin alone is not sufficient to induce metas-
tasis in this tumour model, suggesting that multiple pathways
are involved in the metastatic cascade. However, it is difficult
to relate quantitative changes in exogenous ezrin overexpres-
sion directly with dominant active or negative functional
effects, because the signalling networks involved are complex
and the functional assays are long term (18–36 hours for cell
motility and invasion, and 5 weeks for metastasis). Our focus
was therefore on the qualitative effects on breast cancer
metastasis of blocking ezrin function using a dominant-nega-
tive amino-terminal ezrin mutant [6].
Our finding that Akt S473 phosphorylation is enhanced in
AC2M2 cells compared with parental SP1 cells suggests a
key role for the PI3K/Akt pathway in metastasis. Expression of
amino-terminal ezrin reduced the levels of Akt S473 phospho-
rylation to that of SP1 cells, indicating a dominant regulatory
effect of ezrin on PI3K/Akt signalling in AC2M2 cells. Further-
more, inhibition of PI3K blocked both cell motility and invasion
in AC2M2 cells overexpressing wild-type ezrin, indicating that
PI3K is a downstream effector of ezrin in these functions. In
addition to its role in cell motility via PI3K, ezrin may also par-
ticipate in metastasis by increasing cell survival. Indeed, we
previously showed that ezrin signals cell survival by activating
the PI3K/Akt pathway [5].
Interestingly, although Erk1/2 activation is also reduced in
amino-terminal ezrin-expressing cells, inhibition of the MAPK
pathway has no detectable effect on cell motility or invasion in
this tumour model. However, previous reports have indicated
that an activated MEK mutant can rescue early survival of
metatastic osteosarcoma cells expressing ezrin antisense
[14]. It is therefore possible that an ezrin-dependent MAPK
pathway still plays a role in our breast metastasis model, as
demonstrated by Khanna and coworkers [14].
We also observed a strong increase in cytoskeletal-associ-
ated c-Src pY418 in cells overexpressing wild-type ezrin, and
this effect was abrogated in cells expressing amino-terminal
ezrin. Furthermore, inhibition of c-Src activity partially blocks
cell motility and completely abrogates invasion of ezrin-
expressing AC2M2 cells. These findings are consistent with
our previous demonstration [24] of a reciprocal relationship
between c-Src and ezrin in phosphorylation/activation of these
two proteins, and their role in regulating cell spreading and cell
migration. The interactive role played by ezrin with c-Src in cell
adhesion-dependent functions may provide an important
mechanism by which integrin signals are amplified through the
cytoskeleton. Previous findings from our laboratory [25] and
others [26] have shown that inhibition of specific integrin
function can block metastasis of breast carcinomas. The find-
ings presented here raise the possibility that ezrin and c-Src
are key regulators of integrin-dependent steps in cell invasion
and metastasis.
Because both PI3K and c-Src are key effectors downstream
of ezrin in the cell motility and invasive phenotypes, these sig-
nalling pathways are likely to be rate limiting in the regulation
by ezrin of metastatic progression in vivo. In addition, cooper-
ativity between PI3K and c-Src may be important in regulating
ezrin function in cell motility and invasion, for example through
activation of Rho GTPases [4,13,21]. In addition, interaction of
ezrin with other signalling molecules such as the Na+/H+
exchanger regulatory factor (NHERF-1), recently described to
be altered in breast cancer, may also be involved [27,28]. Fur-
ther investigation is required to assess the relevance of these
downstream pathways in breast metastasis.
Conclusion
In the present study we show for the first time that ezrin is
required for invasion and metastasis of mammary carcinoma
cells. We further show that PI3K and c-Src activities are mod-
ulated by ezrin and are required for ezrin-dependent cell inva-
sion. Because we recently showed that c-Src is also upstream
of ezrin [24], and acts cooperatively with ezrin in deregulating
cell–cell contacts and cell scattering [19], we propose that
coordinate upregulation of ezrin and c-Src activity may be a
key regulatory step in metastatic breast disease. Together, our
findings suggest that ezrin activation may represent an effec-
tive prognostic marker and a potential target for treatment of
invasion and metastasis of human breast cancer.
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